Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
11.82 USD | +0.98% | -4.78% | -45.78% |
25/04 | Truist Securities Cuts Sage Therapeutics' Price Target to $18 From $22, Hold Rating Maintained | MT |
25/04 | Transcript : Sage Therapeutics, Inc., Q1 2024 Earnings Call, Apr 25, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-45.78% | 70Cr | |
+7.00% | 11TCr | |
+10.97% | 11TCr | |
+0.55% | 2.23TCr | |
-12.34% | 2.22TCr | |
-5.20% | 1.94TCr | |
-37.85% | 1.79TCr | |
-6.18% | 1.72TCr | |
+7.88% | 1.43TCr | |
+34.81% | 1.25TCr |
- Stock Market
- Equities
- SAGE Stock
- News Sage Therapeutics, Inc.
- Sage Therapeutics Says US FDA Grants SAGE-718 Orphan Drug Designation for the Treatment of Huntington's Disease